A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
about
Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonistsIn search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptorAdenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.Nicotine and Parkinson's disease: implications for therapy.Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.Adenosine A(2A) receptors in Parkinson's disease treatment.Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intakePreventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Striatal mechanisms underlying movement, reinforcement, and punishment.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Adenosine A2A antagonists in Parkinson's disease: what's next?Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson's disease.Effects of GABAa receptor antagonists on motor behavior in pharmacological Parkinson's disease model in mice.Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian MiceClinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease.A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization.Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain.Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons.Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists
P2860
Q28476722-CF15137F-525E-4A93-A467-4F1200E33A08Q28820807-D920387F-F60E-4301-8C38-5FE53F6FD73EQ34414817-30CC4492-6966-44E6-AFE1-1501FFAD1264Q34602346-5078FBE4-BC34-4874-BE9C-C9C1E38A2CF2Q35601652-66513B48-79CE-47E5-83CC-43F7018E11D9Q35607243-2A0FD166-297B-45D6-8E47-8C5D46579C05Q36047483-DA20CB7F-FB57-42D9-A0F8-94A209A41685Q36973390-58F0D23E-D242-4E0A-8940-0EC2DADC9537Q37172329-656ED927-6A93-47E2-8BF2-AC1B10E42D9AQ37264464-236914F7-70FA-4F6C-8655-F5591B2CBC53Q37431197-650809AC-6EF3-4D67-9126-5D82B5FA155FQ37506507-D7DA9E32-05A5-4694-9EC2-D889B1D5E691Q37844573-095D1E3B-FFCC-44F5-B8FC-24825582FF33Q37924629-D543C41F-CEB6-4405-89A5-6BA5413A5DC3Q38010070-6321DCA1-8415-4CB0-B772-23D5DC672286Q38199744-267AD1A2-0C86-4082-A653-8A987DF206C8Q40462891-0DB9191A-2A93-4588-B73F-B5530CA92733Q41928667-DAD65006-E326-4BD4-A18F-C538D8CF7FDBQ42322627-4AD928D3-533A-4A30-9741-EFBDB50B2CF2Q42970953-68F0C645-A093-41ED-A44F-52BE074E2859Q44311661-11CFC4A2-6D47-4DFE-BD36-41C78B0E7A9CQ45189219-96990B2B-9602-48BC-B839-D55C5D2AD3F2Q46529369-2ED63F37-E763-431B-A00F-541397320C60Q46932031-14E49CAB-7021-4EB3-80AA-22EB403369E2Q48101711-5F62FAB2-2994-4177-8199-56F6D9E87C46Q48384115-CAF01F92-B763-4AF4-917A-BEF70A061F56Q48867898-293098FA-4F1A-4588-894A-02C8A6EF32F4Q57708302-BC57C06D-4BC9-41CF-84DB-764734FD6EE0
P2860
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@ast
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@en
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@nl
type
label
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@ast
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@en
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@nl
prefLabel
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@ast
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@en
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@nl
P3181
P1433
P1476
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
@en
P2093
Peter Jenner
P3181
P356
10.1212/01.WNL.0000095209.59347.79
P407
P433
11 Suppl 6
P577
2003-12-09T00:00:00Z